Jocelyn Côté, Ph.D.

Associate Professor and Canada Research Chair (Tier II) in RNA Metabolism


Degrees

Postdoctoral Fellow, Arginine Methylation, McGill University, 2004
Postdoctoral Fellow, Alternative Splicing, Washington University in St. Louis, 2000
Ph.D. Microbiologie (Alternative Splicing), Université de Sherbrooke, 1998
B.Sc. Biochimie, Université de Sherbrooke, 1992

Contact info:

Center for Neuromuscular Disease
RGN, Rm. 3111a
Phone: 562-5800 x8660
Email: jcote@uottawa.ca

Research Interests:

My long-term research interest is to elucidate the role of arginine methylation in the regulation of post-transcriptional mechanisms, with a focus on how these novel molecular pathways are deregulated in human pathologies, including spinal muscular atrophy (SMA) and cancer.  Below is a brief description of the three major ongoing projects in the laboratory currently.

Project #1: A Role for Arginine Methylation in Spinal Muscular Atrophy.
(Funded by CIHR until 2013 and Families of SMA Canada through 2012)

Context and Rationale ­ There is presently no cure for spinal muscular atrophy (SMA), a genetic neuromuscular disorder that specifically affects lower a­motoneurons in the spinal cord.  SMA is the leading genetic killer of young children, with a prevalence of 1/6000, and is caused by disruption of a gene named Smn.  Despite a large body of work towards clarifying SMN function in all cells, the molecular defect leading to motoneuron­specific pathologies and development of SMA remains unknown.  Motoneurons from SMA mice exhibit normal survival in culture, but reduced axon growth, correlating with mislocalization of b­actin mRNA in distal axons.  In agreement with this observation, SMN is found in granular foci in axons, although the precise nature of these granular bodies as well as the axonal function of SMN remains to be determined.
My work has demonstrated that the Tudor domain of the SMN protein is a “sensor” of arginine methylation in cellular proteins.  Importantly, naturally­occurring mutations in the Tudor domain, that lead to a loss of this “methyl­sensing” capacity, are found in human patients with severe cases of SMA, underscoring the functional relevance of this domain in the etiology of the disease.  We have identified novel SMN Tudor domain interacting proteins from spinal cord tissues, and found that many of these proteins are known components of neuronal RNA granules.  These specialized ribonucleoprotein (RNP) complexes are responsible for the transport and localized expression of mRNAs in axons of neuronal cells.  Based on these observations, we hypothesize that SMN participates in the assembly and function of neuronal RNA granules.

 

 

Specific Objectives and Methodology ­ We will use a unique motoneuron­like cell line that recapitulates SMA axonal defects, by targeting the 3’ UTR of the endogenous SMN mRNA with stably expressed short hairpin RNAs (shRNAs).  This system will enable us to study naturally­occurring Tudor mutations found in human patients with severe type I SMA.  Our experimental approaches will also be complemented with primary motoneuron cultures and tissues from established SMA mouse models.  We are also using a quantitative mass spectrometry approach, termed “SILAC (Stable Isotope Labeling by Amino acids in Cell culture)”, to study SMA.  This approach is used to characterize the composition and stoichiometry of the SMN complex in the nuclear, cytoplasmic, and axonal compartments of motoneurons, at different time points during differentiation.  Since we have previously shown that arginine methylated proteins are often misregulated in SMA cells, we will also use a variation of the SILAC approach, termed “Heavy methyl SILAC”, that will permit the direct and quantitative analysis of endogenous proteins levels AND methylation status in normal vs SMA motoneurons.

 

Project #2: The Contribution of Specific PRMTs and Their Substrates to Breast Cancer (Funded by ‘The Cancer Research Society’ until 2011)

Context and Rationale ­ Recent studies strongly suggest a role for arginine methylation in oncogenesis: (i) arginine methylation of specific proteins by PRMT6 correlates with cellular transformation and tumor metastatic potential; (ii) PRMT1 was shown to be an essential component of a novel mixed lineage leukemia oncogenic transcriptional complex; (iii) PRMT5 expression is upregulated in mantle cell lymphoma and this correlates with increased anchorage­independent cell growth; (iv) AS1411, a drug currently in clinical trial for treatment of various cancers, was recently shown to act by modifying the intracellular localization and activity of PRMT5; (v) we have found that a strictly cytoplasmic alternatively spliced isoform of PRMT1, PRMT1v2, is overexpressed in a number of breast cancer cell lines, and (vi) we have now observed that CARM1, PRMT5, 6 and 7 are also upregulated in breast cancer cells, correlating with arginine methylation profiles of several proteins being perturbed.  We have shown that PRMT1 isoforms have distinct profiles of interacting proteins/substrates, many with potential implications in breast cancer biology.

Hypothesis and Specific Objectives ­ We hypothesize that misregulation of PRMTs and arginine methylation pathways contributes to the etiology of breast cancer.  This project will first use high­density breast tissue arrays in order to rapidly assess the correlation between PRMT expression levels, arginine methylation profiles, and various breast cancer pathological parameters.  Secondly, using RNA interference and a number of well­established experimental models, we will determine which PRMT(s) are required for breast cancer tumorigenesis, focusing initially on PRMT1v2 (which we have found is specifically overexpressed in breast cancer cell lines and solid tumors).  Finally, a novel quantitative proteomics approach (SILAC) will be used to identify in an unbiased fashion the proteins that are aberrantly arginine methylated in breast cancer cells.

Significance ­ Continued efforts to increase knowledge of breast cancer diagnosis and etiology is essential to answer the need for improved prevention and treatment.  This work has the potential to uncover novel pathways involved in cellular transformation and breast tumorigenesis.

 

Project #3: The role of methyl-binding protein TDRD3 in breast cancer (Funded through Canada Research Chair until 2015)

Context and Rationale - Breast cancer is one of the most common cancers affecting Canadian women.  One in nine (11%) Canadian women are expected to develop breast cancer during her lifetime, and on average, 100 Canadian women will die of breast cancer every week.  We are interested in understanding the cellular role(s) of arginine methylation, with a focus on its implication in human pathologies, including breast cancer.  Interestingly, TDRD3, a protein that we have been the first to characterize, has been identified amongst genes whose high expression has a strong predictive value for poor postoperative prognosis of estrogen receptor­negative breast cancers.  Our initial work on TDRD3 has demonstrated that its Tudor domain, can serve as a protein module recognizing methylated arginines in proteins, although its cellular function remains unknown.  We have more recently further characterized TDRD3 and found that it relocalizes to cytoplasmic Stress Granules (SGs) in response to various cellular stresses.
These cytoplasmic foci are sites of mRNA triage that promote cell survival following exposure to stress stimuli.  The hypoxic core of solid tumors represents a pathophysiologic setting where SGs may contribute to tumor cells survival and resistance to chemotherapeutic agents.

Hypothesis: TDRD3, mainly through its role in stress granules, plays a role in promoting late hallmarks of breast cancer pathogenesis, including tumor cells survival, resistance to therapy, and metastasis.

 

Current Lab Members:

Geneviève Paris, M.Sc., Senior Lab Technician
Dr. Gabriel Sanchez, Ph.D., Postdoctoral Fellow (Funded through AFM)
Dr. Robert Mitchum Baldwin, Ph.D., Postdoctoral Fellow (Funded through CIHR)
Helina Tadesse, Ph.D. candidate (Funded through OGS scholarship)
Alan Morettin, Ph.D. candidate
Michelle Prévost, Ph.D. candidate (co-supervized with Dr. L. Trinkle-Mulcahy)
Janik Laframboise, M.Sc. candidate
Yang Xu, M.Sc. candidate (co-supervized with Dr. S. Lee)
Alaa Fanous, M.Sc. candidate
Huidan Sun, NSERC summer student
Muhammad Usama Arabi, Honors student

Alumni:

Benoit Paquette, M.Sc. 2010
Marie-Ève Pelletier, M.Sc. 2010
Lisa Hubers, M.Sc. 2010
Isabelle Goulet, Ph.D. 2011 (pending Thesis evaluation)

 

Publications:

  • Hubers, L., Valderrama-Carvajal, H., Laframboise, J., Sanchez, G. and Côté, J. (2011) HuD interacts with Survival Motor Neuron protein and can rescue SMA-like neuronal defects. Human Molelular Genetics, Advance Access Nov. 2010, 20(3):553-79.
  • Li, P.-C., Chrétien, L., Côté, J., Kelly, T.J. and Forsburg, S.L. (2011) S. pombe replication protein Cdc18 (Cdc6) interacts with Swi6 (HP1) heterochromatin protein: region specific effects and replication timing in the centromere. Cell Cycle, 10(2):323-36.
  • Chen, Y.C., Milliman, E.J., Goulet, I., Côté, J., Jackson, C.A., Vollbracht, J.A. and Yu, M.C. (2010) Protein arginine methylation facilitates co-transcriptional recruitment of pre-mRNA splicing factors. Molecular and Cellular Biology, 30(21):5245-56.
  • Biondi, O., Branchu, J., Deforges, S., Lopes, P., Pariset, C., Lécolle, S., Chanoine, C., Sanchez, G., Côté. J. and Charbonnier, F. (2010) In vivo NMDA-receptor activation accelerates motor unit maturation, protects spinal motor neurons, and enhances SMN2 gene expression in severe spinal muscular atrophy mice. J. Neuroscience, 30(34):11288-99.
  • Zhao, T.T., Cloutier, M., Lewis, S.M., Graber, T.E., Jordan, L, Goulet, I., Côté, J. and Holcik, M. (2009) hnRNP A1 regulates NFkB signaling via destabilization of cIAP1 mRNA. Cell Death and Differentiation, 16(2):244-52.
  • Goulet, I., Boisvenue, S., Mokas, S., Mazroui, R. and Côté, J. (2008) TDRD3, a novel Tudor domain-containing protein, localizes to cytoplasmic stress granules. Human Molecular Genetics, 17(19):3055-74.
  • Khacho, M., Mekhail, K., Pilon-Larose, K., Pause, A, Côté, J. and Lee, S. (2008) A role for the translation machinary in nuclear export. Molecular Biology of the Cell, Accepted for publication.
  • Tadesse, H., Deschenes-Furry, J., Boisvenue, S. and Côté, J. (2008) KH-type splicing regulatory protein interacts with survival motor neuron protein and is misregulated in spinal muscular atrophy. Human Molecular Genetics, 17(4):506-24.
  • Goulet, I., Gauvin, G., Boisvenue, S. and Côté, J. (2007) Alternative splicing yields prmt1 isoforms with distinct activity, substrate specificity and subcellular localization. Journal of Biological Chemistry, 282(45):33009-21.
  • Cheng, D., Côté, J., Shaaban, S. and Bedford, M.T. (2007) The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Molecular Cell, 25(1):71-83.
  • Côté, J. and Richard, S. (2005) Tudor domains bind symmetrical dimethylated arginines. Journal of Biological Chemistry, 280(31):28476-83.
  • Côté, J./Boisvert, F.M., Boulanger, M.C. and Richard, S. (2003) A proteomic analysis of arginine methylated protein complexes. Molecular and Cellular Proteomics, 2(12):1319-30. Epub 2003 Oct 7.
  • Côté, J., Boisvert, F.-M., Boulanger, M.-C., Bedford, M.T. and Richard, S. (2003) Sam68 RNA binding protein is an in vivo substrate for protein arginine Nmethyltransferase 1. Molecular Biology of the Cell, 14(1):274-87.
  • Boisvert, F.-M./Côté, J., Boulanger, M.-C., Cléroux, P., Bachand, F., Autexier, C. and Richard, S. (2002) Symmetrical dimethylarginine methylation is required for the localization of SMN in Cajal bodies and pre-mRNA splicing. Journal of Cell Biology, 159(6):957-69.
  • Bachand, F., Boisvert, F.-M., Côté, J., Richard, S. and Autexier, C. (2002) The Product of the Survival of Motor Neuron (SMN) Gene is a Human Telomerase-Associated Protein. Molecular Biology of the Cell, 13(9): 3192-202.
  • Espejo A., Côté, J., Bednarek A., Richard S., Bedford M.T. (2002) A protein-domain microarray identifies novel protein-protein interactions. Biochemical Journal. 367(Pt 3):697-702.
  • Chen T./Côté, J., Carvajal H.V., Richard S. (2001) Identification of Sam68 arginine glycine-rich sequences capable of conferring nonspecific RNA binding to the GSG domain. Journal of Biological Chemistry. 276(33):30803-11.
  • Côté, J., Dupuis, S. Jiang, Z.H. and Wu, J.Y. (2001) Caspase-2 pre-mRNA alternative splicing: regulation by an intronic element containing a decoy 3’ acceptor site. Proceedings of the National Academy of Science U.S.A. 98(3):938-943.
  • Côté, J., Dupuis, S. and Wu, J.Y. (2001) PTB binding downstream of caspase-2 alternative exon 9 represses its inclusion. Journal of. Biological Chemistry, 276(11):8535- 43.
  • Jiang, Z.H., Côté, J., Kwon, J.M., Goate, A.M. and Wu, J.Y. (2000) Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia FTDP-17. Molecular and Cellular Biology, 20(11):4036-48.

 

© University of Ottawa
For additional information, consult our list of contacts
Technical questions? medtech@uottawa.ca
Last updated: 2011.06.10